Purpose: To prospectively investigate the associations of serum cholinesterase (CHE) levels with ischemic outcomes after angioplasty and stenting for lower limb peripheral artery disease (PAD). Methods: A prospective cohort study enrolled 108 patients with Rutherford category 2–3 ischemia who had successful primary unilateral angioplasty and self-expanding bare metal stent implantation for superficial femoral artery (SFA) stenosis. The primary endpoint was a composite of nonfatal myocardial infarction, nonfatal stroke or transient ischemic attack, cardiovascular death, or >80% target lesion restenosis within 2 years after peripheral angioplasty. Target lesion restenosis (restenosis endpoint) and the composite of the aforementioned atherothrombotic events (atherothrombotic endpoint) within 2-year follow-up were defined as secondary endpoints. Results: CHE levels were not available in 4 patients due to technical problems and 4 patients were lost to follow-up. The remaining 100 patients (median age 65 years; 62 men) met the minimum sample size requirement for statistical analysis. Median CHE levels were significantly lower in patients who subsequently experienced the primary endpoint compared with patients without ischemic events [7.1 (IQR 6.3–8.1) vs 8 (IQR 7–9.3) kU/L, p=0.007]. A CHE level <8.3 kU/L was identified as the best cutoff value to predict the primary endpoint, providing an 82.1% sensitivity and 44.3% specificity. The primary endpoint occurred significantly more often in patients with low CHE <8.3 kU/L than in patients with higher CHE levels (32 vs 7 patients, p=0.01). In multivariable Cox regression analysis, low CHE was associated with a 2.6-fold increased risk (95% CI 1.1 to 5.9, p=0.03) of the primary endpoint. Moreover, patients who suffered the secondary restenosis endpoint had significantly lower median CHE levels than patients without restenosis [7.1 (IQR 6.3–8.2) vs 7.9 (IQR 7–8.9) kU/L, p=0.02], and restenosis occurred more frequently in patients with low CHE compared with those with higher CHE levels (27 vs 7 patients, p=0.04). Conclusion: Low CHE is associated with an increased risk of long-term adverse ischemic events following SFA angioplasty with stent implantation for PAD.
LeeperNJDeweyFEAshleyEA, et al. Prognostic value of heart rate increase at onset of exercise testing. Circulation. 2007;115:468–474.
2.
AdabagASGranditsGAPrineasRJ, et al. Relation of heart rate parameters during exercise test to sudden death and all-cause mortality in asymptomatic men. Am J Cardiol. 2008;101:1437–1443.
3.
JouvenXEmpanaJPSchwartzPJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352:1951–1958.
4.
ColeCRBlackstoneEHPashkowFJ, et al. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999;341:1351–1357.
5.
ArenaRGuazziMMyersJ, et al. Prognostic value of heart rate recovery in patients with heart failure. Am Heart J. 2006;151:851 e857–e813.
6.
SavonenKPKiviniemiVLaukkanenJA, et al. Chronotropic incompetence and mortality in middle-aged men with known or suspected coronary heart disease. Eur Heart J. 2008;29:1896–1902.
7.
SoreqHSeidmanS. Acetylcholinesterase—new roles for an old actor. Nat Rev Neurosci. 2001;2:294–302.
8.
ArbelYShenhar-TsarfatySWaiskopfN, et al. Decline in serum cholinesterase activities predicts 2-year major adverse cardiac events. Mol Med. 2014;20:38–45.
9.
van KuijkJPFluWJWeltenGM, et al. Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease. Eur Heart J. 2010;31:992–999.
10.
WeltenGMSchoutenOHoeksSE, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51:1588–1596.
11.
den BlaauwenDHPoppeWATritschlerW. Cholinesterase (EC 3.1.1.8) with butyrylthiocholine-iodide as substrate: references depending on age and sex with special reference to hormonal effects and pregnancy [in German]. J Clin Chem Clin Biochem. 1983;21:381–386.
12.
GoliaschGKleberMERichterB, et al. Routinely available biomarkers improve prediction of long-term mortality in stable coronary artery disease: the Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) risk score. Eur Heart J. 2012;33:2282–2289.
13.
Ben AssayagEShenhar-TsarfatySOfekK, et al. Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality. Mol Med. 2010;16:278–286.
14.
SchlagerOAmighiJHaumerM, et al. Inflammation and adverse cardiovascular outcome in patients with renal artery stenosis and peripheral artery disease. Atherosclerosis. 2009;205:314–318.
15.
SchillingerMHaumerMSchlerkaG, et al. Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: the role of inflammation. J Endovasc Ther. 2001;8:477–483.
